TruSight Tumor 170 Kit, For Use with NextSeq plus Watson for Genomics
TruSight Tumor 170 Kit plus Watson for Genomics
Results of analysis indicate that TruSight Tumor 170, with comprehensive coverage of cancer-related genes, shows high concordance with whole exome sequencing for accurate assessment of tumor mutational burden.
Standard extractions from FFPE embedded samples provide sufficient material (40ng) in >95% of samples that were extracted by Illumina. This data shows that the TruSight Tumor 170 panel is a robust assay that generates passing sample QC data in >85% of samples with varying quality, and in >95% of samples that have quality metrics that fall within the recommendations for the kit.
TruSight Tumor 170 can achieve high sensitivity and specificity for the detection of somatic variants (small variants and CNVs) from DNA extracted from FFPE tissues.
Through examining limit of detection in the context of RNA expression, this study shows that TruSight Tumor 170 provides high sensitivity and specificity in RNA variant calling down to 5 copies of transcript per ng of input.